CCS
CRSP icon

Crosspoint Capital Strategies’s CRISPR Therapeutics CRSP Stock Holding History

Crosspoint Capital Strategies’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-23,773
Closed -$1.4M – 63
2018
Q2 		$1.4M Buy
+23,773
New +$1.35M 2.67% 25

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Crosspoint Capital Strategies's CRSP Position: Q3 2018 in Review

Crosspoint Capital Strategies sold out of CRISPR Therapeutics (CRSP) in Q3 2018, closing a stake of 23,773 shares — an estimated $1.4M sold.

Crosspoint Capital Strategies first reported a position in CRSP in Q2 2018 and held it in 1 quarter. The position peaked at $1.4M in Q2 2018. 179 funds tracked by Wall St. Rank hold CRSP as of Q3 2018.

  • Crosspoint Capital Strategies reported no remaining CRISPR Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 23,773 CRISPR Therapeutics shares in Q3 2018, an estimated $1.4M.
  • Crosspoint Capital Strategies first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 1 quarter.
  • Crosspoint Capital Strategies's CRISPR Therapeutics position peaked at $1.4M in Q2 2018.
  • 179 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2018.

Based on Crosspoint Capital Strategies's 13F filing for Q3 2018, filed 13 Nov 2018.